Targeting glutamate carboxypeptidase II in IBD

Area of Science:

• Biochemistry
• Immunology
• Gastroenterology

Background:

• Glutamate carboxypeptidase II (GCPII) is a zinc metalloenzyme.
• GCPII is minimally expressed in healthy gut tissue but significantly upregulated in various subtypes of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).

Purpose of the Study:

• To review GCPII biology in the context of IBD.
• To present evidence of GCPII upregulation in IBD patients.
• To discuss the therapeutic potential of GCPII inhibitors for IBD treatment.

Main Methods:

• Review of existing literature on GCPII biology and IBD.
• Analysis of gene and protein expression data confirming GCPII upregulation in IBD.
• Evaluation of preclinical studies on small molecule GCPII inhibitors in colitis models.
• Introduction of a novel class of GCPII inhibitors, including (S)-IBD3540.

Main Results:

• GCPII is profoundly upregulated in adult and pediatric Crohn's disease and ulcerative colitis, including UC pouchitis.
• Small molecule GCPII inhibitors have demonstrated significant efficacy in preclinical models of colitis.
• A novel class of GCPII inhibitors, exemplified by (S)-IBD3540, has been developed.

Conclusions:

• GCPII is a validated therapeutic target for inflammatory bowel disease.
• Small molecule GCPII inhibitors represent a promising therapeutic strategy for IBD.
• (S)-IBD3540 and related compounds offer potential for novel IBD treatments.